Memberships

MetrioPharm

MetrioPharm Memberships

News

MetrioPharm Achieves 50% of Target Patients Randomized in MP1032 Phase II Clinical Trial - 2018-Aug-14

MetrioPharm AG, today announced that more than 50% of patients with moderate-to-severe psoriasis (PASI entry score 10-20) have been randomized in the company’s ongoing Phase II clinical trial.

» more

Investor Relations

MetrioPharm Investor Relations News QII 2018 - 2018-Jun-29

Topics: 12th Annual General Meeting, Investor Talks in Munic, Swiss Biotech Day in Basel, MetrioPharm in Boston, SFRRI Meeting in Lisbon, Investor Talks in Dublin, Corporate Calendar

» more